LENSAR

LENSAR ROE

The Return on Equity (ROE) of LENSAR (LNSR) as of Oct 19, 2026 is 131.75 %. In the previous year, Return on Equity (ROE) was -168.42 % — a change of -178.23% (higher).

ROE

131.75 %

YoY

-178.23%

Last updated:

In 2025, LENSAR's return on equity (ROE) was 131.75 %, a -178.23% increase from the -168.42 % ROE in the previous year.

The LENSAR ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
61.53 USD
Jan 1, 2019
47.97 USD
Jan 1, 2020
-29.42 USD
Jan 1, 2021
-35.72 USD
Jan 1, 2022
-47.43 USD
Jan 1, 2023
-30.49 USD
Jan 1, 2024
-168.42 USD
Jan 1, 2025
131.75 USD
The LENSAR ROE history
YEARROEYoY
131.75 %-178.23%
-168.42 %+452.42%
-30.49 %-35.72%
-47.43 %+32.80%
-35.72 %+21.40%
-29.42 %-161.33%
47.97 %-22.04%
61.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR Inc is a healthcare company based in Orlando, Florida, specializing in femtosecond laser technology for refractive cataract surgery. The company went public on September 21, 2020, and currently employs 150 full-time employees. LENSAR develops and markets femtosecond laser systems designed to treat cataracts and manage pre-existing or surgically induced corneal astigmatism. Its primary products include the LENSAR Laser System, which features Streamline IV and IntelliAxis technologies, along with associated consumable components such as a disposable patient interface device kit. The company also offers the ALLY Adaptive Cataract Treatment System, a compact device integrating femtosecond laser capabilities with enhanced laser features for single-room cataract procedures. LENSAR's technology aims to assist surgeons in achieving optimal visual outcomes during cataract surgery. The company operates within the healthcare sector, focusing on innovative solutions for ophthalmic procedures. Its headquarters in Orlando serves as the central hub for research, development, and business operations. LENSAR's website, lensar.com, provides further details about its products and services. The firm's product portfolio emphasizes precision and efficiency in surgical treatments, targeting healthcare providers seeking advanced tools for cataract management. As a publicly traded entity under the ticker LNSR, LENSAR continues to advance its technological offerings in the medical device industry. LENSAR is one of the most popular companies on Eulerpool.

ROE Details

Decoding LENSAR's Return on Equity (ROE)

LENSAR's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing LENSAR's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

LENSAR's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in LENSAR’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about LENSAR stock

Return on Equity (ROE) of LENSAR is 131.75 % in 2025.

Return on Equity (ROE) of LENSAR changed from -168.42 % to 131.75 %, representing a -178.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) LENSAR since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s LENSAR with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — LENSAR

All Key Metrics — LENSAR